Ascletis Pharma (01672) Announces Share Repurchase and Updated Issued Shares

Bulletin Express

10/27

Ascletis Pharma Inc. (01672) disclosed a share repurchase on 27 October 2025, acquiring 100,000 ordinary shares on the Stock Exchange at prices ranging from HKD 9.58 to HKD 9.73 per share, totaling HKD 969,970. Following this transaction, the number of issued shares (excluding treasury shares) stood at 992,374,320, while treasury shares increased to 6,584,210, maintaining the total of 998,958,530 shares.

Historical repurchase activities for cancellation but not yet canceled were also indicated, involving multiple transactions from 3 April 2025 to 13 October 2025, covering an aggregate of 960,000 shares under the current mandate. As confirmed in the announcement, these repurchases follow applicable regulations, and a moratorium applies until 26 November 2025 for new share issues or disposal of treasury shares.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1110273823"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110273823\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110273823?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110273823","market":"hk","top_or_hot":-1,"title":"Ascletis Pharma (01672) Announces Share Repurchase and Updated Issued Shares","media":"Bulletin Express","content":"<p>Ascletis Pharma Inc. (01672) disclosed a share repurchase on 27 October 2025, acquiring 100,000 ordinary shares on the Stock Exchange at prices ranging from HKD 9.58 to HKD 9.73 per share, totaling HKD 969,970. Following this transaction, the number of issued shares (excluding treasury shares) stood at 992,374,320, while treasury shares increased to 6,584,210, maintaining the total of 998,958,530 shares.</p>\n<p>Historical repurchase activities for cancellation but not yet canceled were also indicated, involving multiple transactions from 3 April 2025 to 13 October 2025, covering an aggregate of 960,000 shares under the current mandate. As confirmed in the announcement, these repurchases follow applicable regulations, and a moratorium applies until 26 November 2025 for new share issues or disposal of treasury shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma (01672) Announces Share Repurchase and Updated Issued Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma (01672) Announces Share Repurchase and Updated Issued Shares\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2025-10-27 19:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Ascletis Pharma Inc. (01672) disclosed a share repurchase on 27 October 2025, acquiring 100,000 ordinary shares on the Stock Exchange at prices ranging from HKD 9.58 to HKD 9.73 per share, totaling HKD 969,970. Following this transaction, the number of issued shares (excluding treasury shares) stood at 992,374,320, while treasury shares increased to 6,584,210, maintaining the total of 998,958,530 shares.</p>\n<p>Historical repurchase activities for cancellation but not yet canceled were also indicated, involving multiple transactions from 3 April 2025 to 13 October 2025, covering an aggregate of 960,000 shares under the current mandate. As confirmed in the announcement, these repurchases follow applicable regulations, and a moratorium applies until 26 November 2025 for new share issues or disposal of treasury shares.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌禮制藥-B","start_time":0,"source_url":"","article_id":"1110273823","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110273823","pubTimestamp":1761565398,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascletis Pharma Inc. (01672) disclosed a share repurchase on 27 October 2025, acquiring 100,000 ordinary shares on the Stock Exchange at prices ranging from HKD 9.58 to HKD 9.73 per share, totaling...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼制药(01672)公布购回股份及更新已发行股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"Ascletis Pharma Inc. (01672) disclosed a share repurchase on 27 October 2025, acquiring 100,000 ordinary shares on the Stock Exchange at prices ranging from HKD 9.58 to HKD 9.73 per share, totaling HKD 969,970. Following this transaction, the number of issued shares (excluding treasury shares) stood at 992,374,320, while treasury shares increased to 6,584,210, maintaining the total of 998,958,530 shares.\nHistorical repurchase activities for cancellation but not yet canceled were also indicated, involving multiple transactions from 3 April 2025 to 13 October 2025, covering an aggregate of 960,000 shares under the current mandate. As confirmed in the announcement, these repurchases follow applicable regulations, and a moratorium applies until 26 November 2025 for new share issues or disposal of treasury shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}